Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EnACT: Oral Amphotericin for Cryptococcal Meningitis
NCT04031833Phase 2Completed
- Sponsor
- Matinas BioPharma
- Start
- Oct 2019
- Primary completion
- Nov 2022
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MAT2203 in cryptococcal meningitis, sponsored by Matinas BioPharma. Started Oct 2019; status: completed.
02
Drugs
MAT2203
03
Conditions
cryptococcal meningitis
Beyond the preview
Go deeper on NCT04031833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04031833.